- ADJUNCT ASSISTANT PROFESSOR Medicine, Nephrology
Dr. Schroppel has recently been appointed the Medical Directory of Transplant Nephrology.
Louis R. Wasserman Medical Scholar Career Development Award
Mentored Clinical Scientist Development Award (K08)
National Institute of Health
Norman S. Coplon Grant, Satellite Research Award
American Society of Transplant Surgeons (ASTS) Vanguard Prize
''Jan Brod'' research award
University of Hannover, Germany
Fresenius medical thesis research award
University of Ulm, Germany
ResearchThe role of donor-derived chemokines in islet transplantation
A major challenge of pancreatic islet transplantation is the protection of the already putatively marginal islet cell mass. Our data demonstrate that islets have the capacity to behave in a similar manner to cells of the immune system, recruiting leukocytes from the blood stream. The hypothesis is that islet-derived mediators directly or indirectly affect islet engraftment, function and viability, and serve to further amplify the adaptive immune response. The goals are to characterize the innate immune response to specific stimuli in islet transplantation and to identify therapeutic strategies to improve islet transplant engraftment and survival.
Genetic studies in Transplantation
Despite a marked improvement in renal transplant rejection rates over the last decade, the improvement in long-term allograft survival remains modest. Recent advances from the Human Genome Project have identified numerous regions of genetic variability, both single-nucleotide polymorphisms (SNP's) and microsatellites regions, within genes relevant to transplantation. Delayed graft function (DGF) is a form of acute renal failure resulting in post-transplantation oliguria, increased allograft immunogenicity and decreased long-term survival. Our ongoing research is based on the following two hypothesis: (1) The susceptibility to DGF is modified by inherited genetic polymorphisms that alter the level of response in genes that are known to modify the response to tissue injury; (2) Distinct gene expression patterns can be identified in the transplanted allograft that can predict DGF and that can reliably discriminate complex mechanisms of DGF.
Fischereder M, Schroppel B. The role of chemokines in acute renal allograft rejection and chronic allograft nephropathy. Frontiers in Bioscience;: in press.
Zang W, Lin M, Kalache S, Zhang N, Kruger B, Waaga-Gasser AM, Grimm M, Hancock W, Heeger P, Schroppel B, Murphy B. Inhibition of the Alloimmune Response Through the Generation of Regulatory T Cells by a MHC Class II-Derived Peptide. J Immunol 2008; 181: 7499-7506.
Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS. The addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3(4): 1160-1167.
Akalin E, Dinavahi R, Dikman S, de Boccardo G, Friedlander R, Schroppel B, Sehgal V, Bromberg JB, Heeger P, Murphy B. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2(6): 1261-1267.
Ommen ES, Schroppel B, Kim JY, Gaspard G, Akalin E, de Boccardo G, Sehgal V, Lipkowitz M, Murphy B. Routine use of ambulatory blood pressure monitoring in potential living kidney donors. Clin J Am Soc Nephrol 2007; 2(5): 1030-1036.
Chen D, Zhang N, Fu S, Schroppel B, Guo Q, Xu J, Garin E, Lira SA, Bromberg JS. CD4+CD25+ T regulatory cells inhibit the islet innate immune response and promote islet engraftment. Diabetes 2006; 55: 1011-1021.
Zang W, Kalache S, Lin M, Schroppel B, Murphy B. MHC class II mediated apoptosis by a non-polymorphic MHC class II peptide proceeds by activation of proteinase C. Am Soc Nephrol 2005; 16(12): 3661-6668.
Schroppel B, Zhang N, Chen P, Chen D, Bromberg JS, Murphy B. Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation. J Am Soc Nephrol 2005 Feb; 16(2): 444-551.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Schroppel during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.